Alemtuzumab (Lemtrada)
Sist oppdatert: Sist revidert:
Sist revidert av:Trygve Holmøy, spesialist i nevrologi
- Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.. Lancet 2012; Nov 24;380(9856): 1819-28. pmid:23122652 PubMed
- Coles AJ, Cohen JA, Fox . Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.. Neurology 2017.
- Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.. Neurology 2017. pmid:28835401 PubMed
- Tuohy O1, Costelloe L2, Hill-Cawthorne G3, Bjornson I1, Harding K4, Robertson N4, May K1, Button T1, Azzopardi L1, Kousin-Ezewu O1, Fahey MT5, Jones J1, Compston DA1, Coles A1..Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2014. pmid:24849515 PubMed
- Katja Thomas, Judith Eisele, Francisco Alejandro Rodriguez-Leal, Undine Hainke, Tjalf Ziemssen. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2016 Jun; 3(3): . pmid:27213173 PubMed
- Mahajan KR. Disseminated nocardiosis with cerebral and subcutaneous lesions on low-dose prednisone. Pract Neurol. 2019 Feb;19(1):62-63. PMID: 30242096 PubMed
- Holmøy T. Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies . BMC Neurol. 2017 . pmid:28376817 PubMed
- Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases. Int J Mol Sci . 2015 ; Jun 29;16(7): 14669-76. PMID: 26132570 PubMed
- Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.. Neurology. 2018 ; Dec 11;91(24):: e2233-e2237. pmid:30404783 PubMed
- Maniscalco GT, Mariotto S, Höftberger R, Capra R, Servillo G, Manzo V, Napolitano M, Candelaresi P, Gerevini S, Ferrari S, Bozzetti S, Spatola M, Florio C. . GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis. Neurology 2020. pmid:32651290 PubMed
- Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77: 573-9. pmid:21795656 PubMed
- Penkert H1, Delbridge C2, Wantia N3, Wiestler B4, Korn T5.. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2016. pmid: 27043129 PubMed
- Gaitán MI, Ysrraelit MC, Correale J. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.JAMA Neurol. 2017 Sep 1;74(9):1143-1144. PMID: 28715536 PubMed
- Azevedo CJ1, Kutz C2, Dix A3, Boster A4, Sanossian N5, Kaplan J3.. Intracerebral haemorrhage during alemtuzumab administration.. Lancet Neurol. 2019; Apr;18(4):: 329-331. pmid:30777657 PubMed
- Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.Lancet Neurol. 2017 Feb;16(2):104-106. PMID: 28102146 PubMed
- Hohlfeld R, Kümpfel T. Alemtuzumab and Multiple Sclerosis: Another Note of Caution.. JAMA Neurol 2016. pmid:27042804 PubMed
- Trygve Holmøy, spesialist i nevrologi, professor dr med
- Elisabeth Gulowsen Celius, spesialist i nevrologi, professor dr med
- Unn Ljøstad, spesialist i nevrologi, professor PhD
- Åse Mygland, spesialist i nevrologi, professor dr med